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PURPOSE. To create a risk model for neovascular age-related macular degeneration (nAMD)
based on nongenetic factors.
METHODS. In this case-control study, 1459 individuals were included, 445 patients showed
nAMD and 1014 were healthy controls. Participants were randomly assigned into a training
set (containing two-thirds of individuals) and a validation set. Stepwise logistic regression
analysis was performed for 25 environmental risk factors in the training set. The risk model
with the remaining factors was then validated in the validation set using receiver operating
characteristics (ROC) curve and Hosmer-Lemeshow-Test. Additionally, a genetic risk model
including variants in the complement factor H gene (CFH, rs1061170) and the age-related
maculopathy susceptibility 2 gene (ARMS2, rs10490924) was generated.
RESULTS. The environmental risk model with the factors age, alcohol use, allergy, education,
sunlight exposure, fish consumption, and physical exercise showed an AUC of 0.80 (95%
confidence interval [CI] 0.76–0.84) in the training set. Validation of the model showed
adequate calibration (Hosmer-Lemeshow P ¼ 0.81). The AUC for the genetic model was 0.77
(95% CI 0.730–0.808), for the combined environmental and genetic model 0.92 (95% CI
0.887–0.947).
CONCLUSIONS. Seven nongenetic factors are able to provide equivalent discrimination between
nAMD patients and controls to genetic risk models. Most of them are modifiable and give the
opportunity for counseling patients.
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Age-related macular degeneration (AMD), especially the lateforms with geographic atrophy of the retinal pigment
epithelium or choroidal neovascularization (CNV), is the
leading cause of severe blindness of the elderly population in
the developed world. The etiology of AMD is multifactorial,
involving genetic and environmental factors. The two major
loci for AMD development are variants in the complement
factor H (CFH) gene and the age-related maculopathy suscep-
tibility 2 (ARMS2) gene, which account for 70% of the genetic
risk.1,2
To predict the risk in complex diseases, analysis of single
aspects is generally of limited value and evaluating multiple
independent disease-associated factors may be more appropri-
ate.3 This can be based on risk models. But so far, they were
either based on exclusively genetic factors4–7 or a combination
of genetic and few nongenetic factors.8–12
Although, besides age, the environmental factors of smok-
ing, cardiovascular risk factors, diabetes, higher body mass
index (BMI), nutrition, and lifestyle factors, such as sunlight
exposure and alcohol consumption, may be associated with
AMD,13–22 an extensive risk model involving environmental
factors has not been established.
In our study, we analyzed 25 nongenetic variables and
developed a risk model for nAMD. Furthermore, we tested the
model with the addition of major genetic polymorphisms.
METHODS
From the European Genetic Database (EUGENDA, www.
eugenda.org), clinical, genetic, and imaging data of 1878
individuals were reviewed. Patients and controls were recruited
from a small area around Cologne, in Western Germany.
Recruitment was initiated by participants and was not
‘‘hospital-based.’’ The study was performed in accordance with
the tenets of the Declaration of Helsinki and the Medical
Research Involving Human Subjects Act (WMO) and was
approved by the local ethics committee. Written informed
consent was obtained from all participants.
Patient data included age (subdivided into 8 groups: 50–60
years, 61–65 years, 66–70 years, 71–75 years, 76–80 years, 81–
85 years, 86–90 years, and >90 years), sex (female/male), BMI
(subdivided in three groups: normal: <25, overweight 25–
29.99 and obese ‡30), marital status (living alone/living
together), highest education level (no school degree or
elementary school, high school, professional education, uni-
versity degree), and iris color (light [blue, gray], medium
[green, hazel], dark [brown]). Medical history was obtained by
an interviewer-assisted questionnaire and included arterial
hypertension, myocardial infarction, angina pectoris, stroke or
transient ischemic attack (TIA), congestive heart failure,
vascular bypass surgery, other heart disease, blood-clotting
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disorder, diabetes, rheumatoid arthritis, thyroid disease, cancer,
liver disease, kidney disease, lung disease, migraine, and
history of allergy (including all types of allergies, but primarily
pollen allergy and house dust mite allergy). Furthermore, data
about the use of platelet inhibitors, nonsteroidal anti-inflam-
matory drugs (NSAIDs), antihypertensive drugs, antidiabetic
drugs, corticosteroids, coumarin derivates, and antiglaucoma-
tous drugs was evaluated (yes/no). Data of the lifestyle factors
smoking (never/ever); regular alcohol use (yes/no); regular (at
least once a week) intake of fruit, vegetables, fish, red meat,
and physical exercise; and past sunlight exposure (more or less
than 8 hours outside activity per day during working life).
For a validated environmental risk model, the dataset was
randomly subdivided into a training set, containing two-thirds
of cases and a validation set containing one-third of cases.
All cases were included that either were controls or had
neovascular AMD (nAMD). Staging of AMD was performed by
grading of retinal images, including stereo color fundus
photographs (FPs) and, if available, fluorescein angiograms
(FAs, available in 40% of cases) and spectral domain optical
coherence tomograms (SDOCTs, available in 81% of cases),
according to the standard protocol of the Cologne Image
Reading Center by certified graders (TR, LE). Patients without
drusen and patients having only small drusen (<63 lm) or
pigmentary changes and fewer than 10 small drusen were
defined as controls. Neovascular AMD was classified as CNV
secondary to AMD in at least one eye. Choroidal neovascular-
ization was termed as choroidal neovascular lesion within the
Early Treatment Diabetic Retinopathy Study grid on FPs, Fas, or
SDOCTs, when there was evidence for fluid, blood, or
fibrovascular tissue on FPs, active classic or occult CNV, or
signs for previous CNV, such as staining scar on FAs and/or
retinal or subRPE fluid and/or tissue on SDOCT.
Genotyping
Genotyping of single nucleotide polymorphisms in the CFH
(Y402H; rs1061170) and ARMS2 (A69S; rs10490924) genes
was performed with TaqMan probes and primers from Applied
Biosystems (Foster City, CA, USA). The assays were analyzed on
the ABI 7900HT system (Applied Biosystems) according to the
protocols provided by the manufacturer.
Statistical Analysis
All calculations were performed using SPSS software version
21.0 (IBM Software and Systems, Armonk, NY, USA). Risk
factors with less than 5% of answers per response option were
excluded. In the training data set, an environmental risk model
for nAMD was created using stepwise logistic regression
analysis with all environmental risk factors. The model was
validated using the Hosmer-Lemeshow test with the equation
T ¼
Xk
i¼1

ðOi  EiÞ2=ðEixEi=niÞ

~v2k2
to check the calibration and the receiver operating character-
istic (ROC) curve and the area under the curve (AUC) to check
the discrimination ability of the model. In addition, the risk
model was applied to the validation set and the Hosmer-
Lemeshow test and the ROC curve and AUC were calculated.
Associations between CFH and ARMS2 and nAMD were
evaluated in the training set by logistic regression analysis.
Both genetic risk factors were combined with the variables of
the environmental risk model and a combined model was
calculated using multivariate logistic regression analysis.
Accordingly, the Hosmer-Lemeshow test, the ROC curve, and
the AUC for the combined model was determined.
RESULTS
The training set contained 291 (29.8%) patients with nAMD
and 685 (70.2%) healthy controls; the validation set included
154 (31.9%) nAMD cases and 329 (68.1%) controls. Mean age
of nAMD patients in the training set was 77.6 6 8.4 years and
70.2 6 7.6 years for controls, 575 (58.9%) were female. In the
validation set, mean age was 77.1 6 8.2 years for nAMD cases
and 70.0 6 7.7 for controls and 285 were female (59.0%).
The variables angina pectoris, stroke or TIA, congestive
heart failure, blood-clotting disorder, vascular bypass surgery,
liver disease, NSAIDs, corticosteroids, coumarin derivates, and
fruit and vegetable intake were excluded from analysis because
less than 5% of answers were given for one response option.
Creation and Validation of Environmental Risk
Model
Stepwise regression analysis was performed by computing the
factors age, regular fish consumption, allergy, regular alcohol
use, physical exercise, sunlight exposure, and education level
as relevant factors associated with the risk of nAMD (Fig. 1).
The model seemed to be well calibrated (Hosmer-Lemeshow
test: P¼ 0.42) and was able to discriminate between cases and
controls quite well (AUC 0.80, 95% confidence interval [CI]
0.76–0.84) (Fig. 2). The risk model was further validated in the
validation set. Calibration and discrimination was similar to the
FIGURE 1. Multivariate logistic regression analysis for the environmental risk model (A) and ARMS2 and CFH (B) displaying ORs and 95% CIs. *As
reference served, no physical exercise, negative history of allergy, nonregular alcohol use, no fish intake, past sunlight exposure of less than 8 hours
daily, and no/elementary school degree (high school displayed exemplarily; OR for professional education 0.59 and for university 0.68).
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values in the training set (Hosmer-Lemeshow test: P ¼ 0.81;
AUC 0.82, 95% CI 0.77–0.87; Fig. 3).
Implication of ARMS2 and CFH in the
Environmental Risk Model
Genetic information was available for ARMS2 in 639 cases
(65.4%) and for CFH in 637 cases (65.2%) in the training set.
Logistic regression analysis of genetic risk factors showed
an association for ARMS2 (for heterozygous risk allele: odds
ratio [OR] 2.90, 95% CI 1.96–4.31, P ¼ 1.21 3 107; for
homozygous risk allele: OR 10.14, 95% CI 5.42–18.99, P¼ 1.01
31013) and CFH (for heterozygous risk allele: OR 2.73, 95% CI
1.75–4.26, P ¼ 9.96 3 106; for homozygous risk allele: OR
9.05, 95% CI 5.38–15.23, P¼1.0031013) with nAMD (Fig. 1).
The ROC curve is displayed in Figure 2 and showed an AUC of
0.77 (95% CI 0.730–0.808; Hosmer-Lemeshow test: P ¼ 0.17;
Fig. 2).
The ROC of environmental and genetic risk factors in a
combined model (full model) resulted in an AUC of 0.92 (95%
CI 0.887–0.947; Hosmer-Lemeshow test: P ¼ 0.71; Fig. 2)
DISCUSSION
Although risk models for AMD based on genetic polymor-
phisms are well established, less is known for nongenetic
factors. Therefore, we developed a nongenetic risk model for
nAMD by evaluating 25 factors. Seven variables allowed a high
discrimination (AUC 0.80) between controls and nAMD
patients and adequate validation in a separate replication
cohort indicates that our model would presumably perform
well in other populations.
The genetic background, especially variants in ARMS2 and
CFH genes are important for AMD development and various
genetic risk models exist.4–7 Our genetic model based on two
polymorphisms in ARMS2 and CFH showed comparable
discrimination (AUC 0.77) to the model created by Jakobsdottir
et al.6 containing three SNPs (0.79), however not reaching the
AUC values of our nongenetic model. Even genetic models
FIGURE 2. The ROCs for the discrimination between nAMD and no AMD showed an AUC of 0.80 (95% CI 0.764–0.841) for the environmental
model, 0.77 (95% CI 0.730–0.808) for the genetic model, and 0.92 (95% CI 0.887–0.947) for the full model.
FIGURE 3. Comparison of risk deciles in the training set and the
validation set for the environmental risk model.
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consisting of up to 19 SNPs could not approach better
discrimination between AMD cases and controls,4,5,7 indicating
that even highly associated SNPs may not always be effective as
classifiers6 and underlining the crucial role of the environmen-
tal factors. The addition of only two genetic polymorphisms
increased the AUC to 0.92, which is higher than in any other
cross-sectional study combining environmental and genetic
factors.8,10,12 Other risk models included genetic factors and
systemic biomarkers9,11; however, they also revealed lower
discrimination than our combined model. Only in longitudinal
progression models did AUC also reach levels above 0.90
depending on the inclusion of phenotypic baseline character-
istics.19,23–25
Of 25 factors that were analyzed, 7 factors were identified
as important for discrimination: age, alcohol use, allergy, fish
consumption, education, sunlight exposure, and physical
exercise.
In our cohort, regular alcohol use was associated with
nAMD. Our results are in line with previous reports.26–28
Alcohol is a drug that could be avoided to lower the risk for
AMD development.
A positive history of allergy was found to have a protective
effect for nAMD in our cohort, which was also found in
another study.29 Literature regarding allergy and AMD is limited
and the relationship between these two common conditions is
not yet understood and should be investigated in further
studies.
The protective effect of a higher education level for AMD
development goes in line with previous reports.15,30 The
explanation for the effect may be difficult. Different education
levels may come along with other behavioral and lifestyle
factors, which are not identified yet.
Regular physical exercise is known to be protective for
various diseases, for example coronary heart disease and type 2
diabetes.31,32 The Beaver Dam Eye Study has shown that
patients with an active lifestyle were less likely to develop
nAMD.33 In our cohort, nAMD appeared significantly less
frequently in patients with weekly physical exercise, revealing
that constant physical activity may be effective for AMD
prevention.
Sunlight exposure has been shown to be a risk factor for
AMD in epidemiological studies.22 This finding could also be
confirmed in our cohort. Protection against sunlight may also
help to lower the risk of developing nAMD.
Previous reports could show the protective effects of high
fish intake.34,35 In our study, regular fish intake also was a
protective factor against nAMD and can be recommended.
Many of the ascertained nongenetic factors in our model
could be modified to eventually reduce the occurrence of
nAMD and patients may contribute actively to reduce the risk
for CNV by omitting alcohol and following an active lifestyle.
Our data demonstrate that a model based on factors that can be
fast and easily obtained by a few questions has a high accuracy
and involves obviously less cost than any genetic analysis.
Our study was well powered, validated in a separate
sample, and included a high number of nAMD patients. To our
knowledge, this is the first study to analyze most of the
currently known nongenetic factors developing a risk model to
predict nAMD.
Additionally, multimodal imaging for AMD staging in
EUGENDA reduced misclassification of AMD phenotypes.
Limitations of our study are the use of questionnaires for
evaluation of medical history. It might be assumed to be a
limitation but also a strength that our study included
exclusively nAMD cases with CNV in at least one eye, as well
as controls with no signs of early or late AMD in any eye. The
neovascular form of AMD is important for patients, causing
significant visual impairment. Additionally, the possibility of
interactions among the environmental factors (e.g., a coinci-
dence of high alcohol use and low fish intake or higher
education and a possibly more active lifestyle) cannot be
excluded, but the composition of a stepwise regression model
ensures that each included risk factor has an additional
essential effect on the model.
In summary, our analysis revealed the important role of a
few environmental factors that allow accurate discrimination
between controls and nAMD cases that are equivalent to
genetic risk models.
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